Avenue Therapeutics is a specialty pharmaceutical company whose mission is to develop IV tramadol, a potential alternative that could reduce the use of conventional opioids, for patients suffering from acute pain in the U.S. Avenue is headquartered in New York City and was founded by Fortress Biotech, Inc.
Company profile
Ticker
ATXI
Exchange
Website
CEO
Lucy Lu
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ATXI stock data
Latest filings (excl ownership)
8-K
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates
8 Mar 23
8-K
Entry into a Material Definitive Agreement
2 Mar 23
D
$242.54 k in options, sold $242.54 k, 1 investor
14 Feb 23
S-8
Registration of securities for employees
10 Feb 23
8-K
Amendments to Articles of Incorporation or Bylaws
10 Feb 23
8-K
Departure of Directors or Certain Officers
3 Feb 23
8-K
Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
1 Feb 23
424B5
Prospectus supplement for primary offering
31 Jan 23
8-K
Changes in Registrant's Certifying Accountant
25 Jan 23
DEFA14A
Additional proxy soliciting materials
17 Jan 23
Latest ownership filings
SC 13G/A
CVI Investments, Inc.
14 Feb 23
SC 13D/A
Fortress Biotech, Inc.
6 Jan 23
4
Change in insider ownership
4 Jan 23
SC 13G
SABBY MANAGEMENT, LLC
4 Jan 23
SC 13G/A
Nantahala Capital Management, LLC
14 Dec 22
SC 13D/A
InvaGen Pharmaceuticals, Inc.
19 Oct 22
SC 13G
CVI Investments, Inc.
17 Oct 22
SC 13G
INTRACOASTAL CAPITAL, LLC
17 Oct 22
4
Change in insider ownership
13 Oct 22
3
Alexandra MacLean
3 Aug 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 217.00 k | 217.00 k | 217.00 k | 217.00 k | 217.00 k | 217.00 k |
| Cash burn (monthly) | 224.33 k | 30.67 k | 221.00 k | 420.42 k | 184.67 k | 385.83 k |
| Cash used (since last report) | 1.35 mm | 184.11 k | 1.33 mm | 2.52 mm | 1.11 mm | 2.32 mm |
| Cash remaining | -1.13 mm | 32.89 k | -1.11 mm | -2.31 mm | -891.69 k | -2.10 mm |
| Runway (months of cash) | -5.0 | 1.1 | -5.0 | -5.5 | -4.8 | -5.4 |
Institutional ownership, Q3 2022
18.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 12 |
| Opened positions | 5 |
| Closed positions | 12 |
| Increased positions | 1 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 3.65 mm |
| Total shares | 10.74 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| InvaGen Pharmaceuticals | 10.66 mm | $2.89 mm |
| Citadel Advisors | 35.87 k | $362.00 k |
| Two Sigma Investments | 14.34 k | $145.00 k |
| Two Sigma Securities | 14.16 k | $143.00 k |
| WFC Wells Fargo & Co. | 4.54 k | $46.00 k |
| BLK Blackrock | 1.94 k | $20.00 k |
| MS Morgan Stanley | 1.47 k | $15.00 k |
| Tower Research Capital | 1.43 k | $14.00 k |
| UBS UBS Group AG - Registered Shares | 1.14 k | $11.00 k |
| Emfo | 533.00 | $5.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Jan 23 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 231,316 | 0.00 | 561,561 |
| 31 Dec 22 | Fortress Biotech | COMMON STOCK, PAR VALUE $0.0001 | Grant | Acquire A | No | No | 0 | 90,909 | 0.00 | 330,245 |
| 11 Oct 22 | InvaGen Pharmaceuticals | Common Stock, par value $0.0001 per share | Sell | Dispose S | No | No | 7.714 | 388,888 | 3.00 mm | 0 |
News
Annji Pharmaceutical Has Entered Into An Exclusive License Agreement With Avenue Therapeutics For AJ201 For Spinal And Bulbar Muscular Atrophy, Also Known As Kennedy's Disease; Upfront Payment Of $3M, Milestone Payments Of Upto $250M
10 Mar 23
Why JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
9 Mar 23
12 Health Care Stocks Moving In Thursday's Intraday Session
9 Mar 23
12 Health Care Stocks Moving In Thursday's Pre-Market Session
9 Mar 23
Why Cassava Sciences Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
9 Mar 23
Press releases
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease
10 Mar 23
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates
8 Mar 23
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy
2 Mar 23
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)
31 Jan 23
Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement
31 Jan 23